{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:05:19Z","timestamp":1770750319662,"version":"3.50.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z200020"],"award-info":[{"award-number":["Z200020"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05791-1","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:33:33Z","timestamp":1768419213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax-based therapy in high-risk patients with relapsed\/refractory multiple myeloma harboring t(11;14): a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"given":"Junjing","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"24","key":"5791_CR1","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"key":"5791_CR2","unstructured":"[Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(5):430\u20135."},{"issue":"4","key":"5791_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u201376.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"5791_CR4","first-page":"483","volume":"130","author":"A Salomon-Perzy\u0144ski","year":"2020","unstructured":"Salomon-Perzy\u0144ski A, Bluszcz A, Krzywdzi\u0144ska A, Spyra-G\u00f3rny Z, Jakacka N, Barankiewicz J, et al. The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma. Pol Arch Intern Med. 2020;130(6):483\u201391.","journal-title":"Pol Arch Intern Med"},{"key":"5791_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0191-y","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019. https:\/\/doi.org\/10.1038\/s41408-019-0191-y.","journal-title":"Blood Cancer J"},{"key":"5791_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","volume":"41","author":"A Paner","year":"2020","unstructured":"Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020;41: 100643.","journal-title":"Blood Rev"},{"issue":"10","key":"5791_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5(10): e365-e.","journal-title":"Blood Cancer J"},{"issue":"36","key":"5791_CR8","first-page":"2868","volume":"102","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu YF, Tao Y, Jin SW, Mi JQ. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)]. Zhonghua Yi Xue Za Zhi. 2022;102(36):2868\u201373.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"5791_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.034","author":"A Lakshman","year":"2017","unstructured":"Lakshman A, Moustafa MA, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi F, et al. Natural history of t(11;14) multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017. https:\/\/doi.org\/10.1016\/j.clml.2017.03.034.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5791_CR10","doi-asserted-by":"crossref","unstructured":"Touzeau C DC, Le Couill S. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2024;28(1): 210\u20132","DOI":"10.1038\/leu.2013.216"},{"issue":"22","key":"5791_CR11","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139.","journal-title":"Blood"},{"issue":"12","key":"5791_CR12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630\u201342.","journal-title":"Lancet Oncol"},{"issue":"32","key":"5791_CR13","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho S-J, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39(32):3602\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5791_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96(4):418\u201327.","journal-title":"Am J Hematol"},{"issue":"19","key":"5791_CR15","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(19):3748\u201359.","journal-title":"Blood Adv"},{"key":"5791_CR16","first-page":"1","volume":"2020","author":"S Valliani","year":"2020","unstructured":"Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, et al. Efficacy of venetoclax and dexamethasone in refractory IgM primary plasma cell leukemia with t(11;14) and TP53 mutation: a case report and literature review. Case Rep Hematol. 2020;2020:1\u20136.","journal-title":"Case Rep Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05791-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:14:46Z","timestamp":1770722086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-025-05791-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5791"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05791-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and patient informed consent have been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}